![]() ![]() I don’t think they saw a significant difference compared to what we have seen in the previous trials with enzalutamide.īut I think that the uniqueness of darolutamide is the chemical structure and the ability to perhaps not have the CNS and neurocognitive dysfunction that most of you have discussed,by virtue of the lack of penetrance in the CNS. Although, there is a trial called the UPWARD study that Michael Morris, and Susan Slovin, from Memorial Sloan Kettering Cancer Center published, aimed at studying enzalutamide in patients who were at risk for seizure activity. I think part of that has to do with his prior history of seizure activity. ![]() Garcia, MD, FACP: After significant discussions between the patient and the providers, darolutamide was initiated in this patient.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |